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BACKGROUND: An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS)
showed no signiﬁcant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour
of clomifene citrate plus metformin compared with clomifene citrate. We wanted to assess whether there are speciﬁc
subgroups of women with PCOS in whom clomifene citrate plus metformin leads to higher pregnancy rates.
METHODS: Subgroup analysis based on clinical and biochemical parameters of 111 women randomized to clomifene
citrate plus metformin compared with 114 women randomized to clomifene citrate plus placebo. The data for age,
BMI, waist–hip ratio (WHR) and plasma testosterone were available in all women, 2 h glucose in 80% of women
and homeostatic model assessment for assessing insulin sensitivity (HOMA) in 50% of women. RESULTS: Of the
women who were allocated to the metformin group, 44 women (40%) reached an ongoing pregnancy. In the
placebo group, 52 women (46%) reached an ongoing pregnancy. There was a signiﬁcantly different chance of an
ongoing pregnancy for metformin versus placebo between subgroups based on age and WHR (P 5 0.014). There
was a positive effect of metformin versus placebo on pregnancy rate in older women ( 28 years) with a high
WHR, a negative effect of metformin versus placebo in young women (<28 years) regardless of their WHR and no
effect in older, not viscerally obese women. No signiﬁcant differences in effect of treatment were found for groups
based on BMI, 2 h glucose, HOMA or plasma testosterone. CONCLUSIONS: Metformin may be an effective addition
to clomifene citrate in infertile women with PCOS, especially in older and viscerally obese patients.
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Introduction
Polycystic ovary syndrome (PCOS) is characterized by
oligo-anovulation, clinical or biochemical hyperandrogenism
and/or polycystic ovaries (Franks, 1995; Knochenhauer
et al., 1998; Fauser, 2004). Insulin resistance (IR) accompanied
by compensatory hyperinsulinaemia constitutes another major
biochemical feature of PCOS (Nestler and Jakubowicz, 1996;
Dunaif, 1997; Nestler, 1997; Jakubowicz et al., 2001;
Fleming et al., 2002). The syndrome affects 5–10% of
women during reproductive age (Asuncion et al., 2000).
Because of the link between IR and PCOS, metformin has
been put forward as a drug to induce ovulation in women
with PCOS. In fact, metformin either alone or in combination
with clomifene citrate is now the most widely used insulin-
sensitizer for ovulation induction in women with PCOS
(Nestler, 2002; Glueck et al., 2003; ASRM, 2004). The
rationale of this treatment was based on only a few small
studies with conﬂicting results (Nestler et al., 1998; El-Biely
and Habba, 2001).
Recently, we demonstrated in an RCT among newly diag-
nosed, therapy naive women with PCOS that there were no sig-
niﬁcant differences in either ovulation rate, ongoing pregnancy
rate or spontaneous abortion rate in women using clomifene
citrate plus metformin compared with women using clomifene
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ongoing pregnancy rates have been conﬁrmed in another
large RCT (Legro et al., 2007).
However, PCOS is a heterogeneous condition and thus both
studies included a heterogeneous group of women. Surpris-
ingly, there is only one small study involving 32 patients
with PCOS that has investigated the effect of metformin in
speciﬁc subgroups. This study showed in a multivariable analy-
sis that higher insulin, lower androstenedione and less severe
cycle abnormalities appeared to be independent signiﬁcant par-
ameters for better response to metformin (Moghetti et al.,
2000).
Increasing age and high waist–hip ratio (WHR) are known
risk factors in developing IR and, as such, these factors may
also affect clinical response to metformin (Despres, 1993;
Legro et al., 1999; Pasquali et al., 2000; NCEP Expert Panel,
2001; Laine and Wilson, 2007). Apart from these parameters,
some authors suggest that metformin would most likely be
beneﬁcial in women with high BMI (Lord, et al., 2003).
Thus, although many investigators claim a beneﬁcial effect
of metformin in speciﬁc subgroups of women, the evidence
is limited.
We therefore wanted to determine whether co-treatment
with metformin improves pregnancy rates compared with the
standard treatment of clomifene citrate alone in subgroups of
women based on clinical and biochemical variables. For this
purpose, we reanalysed the data from a previously published
randomized trial.
Materials and Methods
The data used in this study were collected in an RCT that has been
reported elsewhere (Moll et al., 2006). This double blinded trial
took place from June 2001 to May 2004 in 20 Dutch hospitals. All
patients with chronic anovulation (a menstrual cycle  35 days),
World Health Organization type II criteria (normogonadotrophic nor-
moestrogenic oligo- or anovulation), polycystic ovaries diagnosed by
transvaginal ultrasonography and a desire to conceive were randomly
allocated to clomifene citrate (50–150 mg a day for ﬁve consecutive
days in the beginning of a menstrual cycle, per os) plus metformin
(500 mg 4/day) or to clomifene citrate plus placebo. Primary exclu-
sion criteria were other causes of anovulation, age over 40 years and
liver, kidney or heart disease/failure (i.e. abnormal results on liver
function tests, serum creatinine concentration .95 mmol/lo ra
history of heart disease/failure) and sperm quality indicating male
subfertility (total motile count ,10   10
6).
Randomization was carried out in the coordinating centre (AMC,
Amsterdam), using computer-generated blocks of four. The containers
with study medication were prepared by Merck Sante ´, France. The ran-
domization was stratiﬁed per centre, and the centres received blinded,
numbered containers with medication. Each included patient received
the container with the next number in their own hospital.
Patients continued to take the study medication until a positive
pregnancy test (4 weeks after the ﬁrst day of menstruation), six ovula-
tory cycles or clomifene citrate resistance occurred, whichever came
ﬁrst. Women had to discontinue their medication as soon as they
had a positive pregnancy test as the safety and beneﬁt of using metfor-
min during pregnancy have not yet been proven.
Ongoing pregnancy was deﬁned as a viable pregnancy at 12 weeks
of gestation. The study was approved by the Institutional Review
Boards of all hospitals. Written informed consent was obtained from
all participants.
At the start of the study, we measured height, weight, WHR and
plasma testosterone.Testosteronewas measuredinseverallaboratories.
Total plasma testosterone concentrations were determined using an
in-house radioimmunoassay, without extraction and chromatography
and with tritiated testosterone as label (Pratt et al., 1975). Intra-assay
and inter-assay coefﬁcients of variation were 4-7% and 5–9%, respect-
ively. An oral glucose tolerance test was also performed. Subgroup
analysis was performed on age, BMI, WHR, testosterone, 2 h glucose
and HOMA (homeostatic model assessment for assessing insulin sensi-
tivity) as a measure of IR (Ehrmann et al., 1999; Legro et al., 1999,
2004; NCEP Expert Panel, 2001; Fauser, 2004; Samaras et al.,
2006).Sincenotalldatawereavailableforallwomen,insomeanalyses
only a proportion of the women could be included.
The subgroup analysis which we present here was planned in the
original protocol. The parameters to be analysed were chosen, after
completion of the trial, according to the most recent literature
(Despres, 1993; Legro et al., 1999; Moghetti et al., 2000; Pasquali
et al., 2000; NCEP Expert Panel, 2001; Lord, et al., 2003; Laine
and Wilson, 2007).
Data analysis
For this subgroup analysis, we explored differences in treatment effect
on ongoing pregnancy rate in subgroups deﬁned on age, BMI, WHR,
plasma testosterone, 2 h glucose level and IR evaluated by HOMA-IR.
For this purpose, we performed logistic regression analysis including
treatment, the subgroup indicator and the interaction between treat-
ment and subgroup.
We assessed the linearity of the association between the continuous
variables age, BMI, WHR, testosterone, 2 h glucose level and HOMA
and the ongoing pregnancy rate using spline functions (Harrell et al.,
1988). Non-linear associations were accommodated by redeﬁning the
corresponding variables.
By testing the interaction in logistic regression, we compared
directly the effect sizes of treatment for the subgroups. If the inter-
action is statistically signiﬁcant, this is a clear indication that the
effect of treatment differs between subgroups (Matthews and
Altman, 1996).
Next, to explore potential interesting subgroup features, we
combined subgroups for which the interaction with treatment was
P , 0.20. In all analyses, P-values , 0.05 were considered signiﬁ-
cant. Data were analysed using the Statistical Package for the Social
Sciences 11.5.1.
Results
Baseline characteristics are presented in Table I. Out of the 111
women in the clomifene citrate plus metformin group, 44
(40%) reached an ongoing pregnancy versus 52 (46%) of the
114 women in the clomifene citrate group, a difference
which was not signiﬁcant [relative risk (RR) 0.87; 95% conﬁ-
dence interval (CI) 0.64–1.2]. A signiﬁcantly larger proportion
of patients in the metformin group discontinued treatment
because of side effects (18/111 versus 6/114; RR 2.9; 95%
CI 1.2–7.1). The total dropout rate in both treatment arms
was not statistically different (28/111 versus 21/114; RR
1.3; 95% CI 0.82–2.2).
The data for age, BMI, WHR and testosterone levels were
complete. The data for 2 h glucose level were available in
80% of patients, and for HOMA, in 50% of patients.
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placebo showed a small trend towards a different effect com-
pared with the effect of metformin versus placebo in women
,28 years (P-value of interaction 0.11) (Table II). In women
with a WHR   0.85, the effect of metformin versus placebo
was signiﬁcantly different from the effect of metformin
versus placebo in women with a WHR , 0.85 (P-value of
interaction 0.012) (Table II).
We did not ﬁnd signiﬁcant differences in effect of treatment
for groups based on BMI, plasma testosterone, 2 h glucose
values or HOMA.
On the basis of these ﬁndings, we combined age and WHR
and created four subgroups. We found a signiﬁcantly different
chance of reaching an ongoing pregnancy of metformin versus
placebo between these subgroups (P-value of interaction
0.014) (Table III). A positive effect of metformin versus
placebo on pregnancy rate was found in older women ( 28
years) with a WHR   0.85, a negative effect of metformin
versus placebo in young women regardless of their WHR and
no effect in the older, not viscerally obese women (Fig. 1).
Discussion
In the present analysis, there was a signiﬁcantly different
chance of an ongoing pregnancy of metformin versus
placebo between subgroups, based on age and WHR. A posi-
tive effect of metformin versus placebo on pregnancy rate
was found in older women with a high WHR, a negative
effect of metformin versus placebo in young women regardless
of their WHR and no effect in older, not viscerally obese
women.
We have included women with PCOS, who had never used
clomifene citrate and were seeking treatment for their fertility
problems forthe ﬁrst time.We evaluated eligibility irrespective
of their BMI. By using these criteria, our study group reﬂects
the largest group of women with PCOS a fertility clinic will
see and treat.
Our results contradict those from the only other subgroup
analysis, where no differential effect of metformin was
shown in subgroups of women based on age and WHR
(Moghetti et al., 2000): this study did show that in multivari-
able analysis higher insulin, lower androstenedione and less
Table I. Baseline characteristics of patients with PCOS who were treated with clomifene citrate plus metformin or clomifene citrate alone. Figures are mean
(SD) unless stated otherwise.
Characteristics n (metformin versus placebo) Clomifene citrate and metformin Clomifene citrate and placebo
Total 111 versus 114
Age (years) 111 versus 114 27.9 (3.7) 28.4 (4.7)
Parity N (%)
Nulliparous 89 versus 95 89 (80%) 95 (84%)
Multiparous 22 versus 18 22 (20%) 18 (16%)
Duration of desire to conceive (years) 100 versus 107 1.6 (1.2) 1.3 (1.1)
BMI (kg/m
2) 104 versus 109 28 (7.1) 27 (6.7)
WHR 102 versus 103 0.82 (0.1) 0.83 (0.1)
LH/FSH ratio 106 versus 109 1.9 (1.3) 2.1 (1.4)
Testosterone (nmol/l) 104 versus 108 3.5 (3.7) 3.6 (3.5)
Free androgen index 70 versus 69 12 (18) 12 (12)
Volume ovaries (ml) 71 versus 65 9.1 (6.1) 10.1 (4.9)
Total motile sperm count (10
6) 102 versus 105 134 (223) 222 (370)
Glucose, fasting (mmol/l) 101 versus 99 4.9 (0.7) 4.9 (0.6)
Glucose, 2 h (mmol/l) 91 versus 90 5.0 (1.4) 5.1 (1.3)
Insulin, fasting (pmol/l) 56 versus 59 85 (169) 60 (131)
Insulin, 2 h (pmol/l) 58 versus 57 233 (274) 270 (386)
HOMA 56 versus 57 11 (12) 10 (11)
HOMA, homeostatic model assessment for assessing insulin sensitivity; WHR, waist–hip ratio.
Table II. Pregnancy rates for subgroups of women with PCOS treated with clomifene citrate plus metformin or clomifene citrate alone.
N Metformin n/N (%) Placebo n/N (%) RR (95% CI) P-value of interaction
Overall 225 44/111 52/114 0.87 (0.64–1.2) —
Age (years),28 years 91 13/48 (27) 19/43 (44) 0.61 (0.35–1.1) 0.11
Age (years)28 years 134 31/63 (49) 33/71 (47) 1.1 (0.74–1.5)
BMI (kg/m
2),28 118 27/56 (48) 32/62 (52) 0.93 (0.65–1.3) 0.23
BMI (kg/m
2)28 95 16/48 (30) 19/47 (40) 0.82 (0.49–1.4)
WHR , 0.85 134 33/70 (47) 37/64 (58) 0.82 (0.59–1.1) 0.012
WHR  0.85 71 10/32 (31) 11/39 (28) 1.1 (0.54–2.3)
Testosterone (nmol/l)3.5 143 30/71 (42) 34/72 (47) 0.89 (0.62–1.3) 0.87
Testosterone (nmol/l).3.5 69 13/33 (39) 15/36 (42) 0.95 (0.53–1.7)
Glucose 2 hours (mmol/l)5 101 22/48 (46) 28/53 (53) 0.87 (0.58–1.3) 0.22
Glucose 2 hours (mmol/l).58 0 1 6 /43 (37) 12/37 (32) 1.1 (0.63–2.1)
HOMA , 3.8 42 10/23 (44) 6/19 (32) 1.4 (0.61–3.1) 0.88
HOMA  3.8 71 13/33 (39) 14/38 (37) 1.1 (0.59–1.9)
RR, relative risk; CI, conﬁdence interval.
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meters for better response to metformin, variables we did not
assess in our study. However, our data may be more valid,
because we analysed over 200 patients, 10 times more than
in the Moghetti et al. (2000) subanalysis and because our
study was based on a double-blinded RCT as opposed to the
open protocol used in the previous subanalysis.
The most likely reason why metformin has a beneﬁcial effect
on pregnancy rates in older and viscerally obese women is that
IR is common in these women (Cowie et al., 2006; Lord et al.,
2006). However, we did not ﬁnd a signiﬁcant interaction
between pregnancy rates and the outcome of other surrogate
markers of IR, including BMI, plasma testosterone, 2 h
glucose value and HOMA. This is probably due to the fact
that WHR is the most powerful predictor of IR of all surrogate
markers (Rexrode et al., 1998; Lord et al., 2003; Alberti et al.,
2006; Lord et al., 2006). We did not measure IR directly by
means of the gold standard, the glucose clamp technique,
since this is considered to be too invasive and burdensome to
be part of a large clinical trial in outpatients (Legro et al.,
2004; Mohlig et al., 2006; Piche et al., 2007).
The lack of effect of metformin in patients with high BMI,
increased plasma testosterone, higher 2 h glucose levels and
HOMA may be real, if conﬁrmed by further studies.
However, another possibility is that the present study did not
have enough power to show a difference. This might especially
hold true for HOMA, since we only had data on half of the
patients.
A limitation of the study is that we did not collect all para-
meters in all patients. In particular, fasting insulin is missing
in 49% of the patients. When comparing baseline character-
istics of the patients for whom data on insulin were available
with those for whom data were not available, we found no
signiﬁcant differences (data not shown). The lack of data
appears, therefore, tobe due toa random effect of notexecuting
the complete study protocol rather than a deliberate omission of
patients with certain clinical or biochemical characteristics.
An additional limitation of the study relates to the testoster-
one analysis. After our study protocol was written (1999) and
our study performed (2001–2004), it became clear that testo-
sterone assays show a wide inter-laboratory variability (Kane
et al., 2007; Rosner et al., 2007). When we had ﬁnished the
trial, it was impossible to adjust for this. The calculations per-
formed in this trial were therefore performed without correct-
ing for this inter-laboratory imprecision, as is the case in all
previous literature. It is possible that the variation is sufﬁ-
ciently high to render the result not signiﬁcant. This relatively
new understanding of the variability of testosterone assays may
have great impact, not only on existing but also on future litera-
ture on PCOS, especially in multicentre studies.
Our RCT was not powered for these subgroup analyses;
therefore, the data need to be interpreted with great caution.
Nonetheless, we feel that our data argue for performing a
trial comparing metformin and clomifene citrate with clomi-
fene citrate alone in older visceral obese women with PCOS.
Conclusion
Although our initial randomized trial showed no beneﬁt for
metformin, our current ﬁndings suggest that metformin may
be an effective addition to clomifene citrate in infertile, older
and visceral obese women with PCOS. Randomized studies
should be performed speciﬁcally for this subgroup, or data
from other existing trials should be re-analysed before we
can consider implementing these ﬁndings in clinical practice.
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